Cargando…
Severe idiopathic pulmonary fibrosis: what can be done?
Idiopathic pulmonary fibrosis (IPF) remains a challenging disease to manage. Two drugs are now available that can slow disease progression in patients with mild-to-moderate IPF. This means that early diagnosis is mandatory, because there are no proven effective therapies for severe IPF. This lack of...
Autores principales: | Caminati, Antonella, Cassandro, Roberto, Torre, Olga, Harari, Sergio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488930/ https://www.ncbi.nlm.nih.gov/pubmed/28954763 http://dx.doi.org/10.1183/16000617.0047-2017 |
Ejemplares similares
-
Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue
por: Caminati, Antonella, et al.
Publicado: (2019) -
Recent advances in managing idiopathic pulmonary fibrosis
por: Scelfo, Chiara, et al.
Publicado: (2017) -
Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences
por: Harari, Sergio, et al.
Publicado: (2015) -
Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation
por: Caminati, Antonella, et al.
Publicado: (2015) -
Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy
por: Harari, Sergio, et al.
Publicado: (2016)